相关实验视频

Updated: Jan 10, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

miR-155-5p沉默不会改变CLL T细胞中的BTLA分子表达:针对性免疫疗法的影响

Agata Kosmaczewska¹, Lidia Ciszak¹, Anna Andrzejczak²

¹Laboratory of Immunopathology, Department of Experimental Therapy, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.

|November 27, 2025

概括

这项研究研究了miR-155-5p在慢性淋巴细胞白血病 (CLL) T细胞中的作用. 用抗miR-155-5p免疫疗法向miR-155-5p是CLL治疗的一个有希望的策略.

科学领域:

免疫学免疫学免疫学
分子生物学分子生物学
在瘤学瘤学.

背景情况:

微RNA-155-5p (miR-155-5p) 在慢性淋巴细胞白血病 (CLL) 外周血液单核细胞 (PBMC) 中升高.
减少miR-155-5p部分恢复了CLL B细胞中的免疫检查点蛋白BTLA.
在T细胞中BTLA的表达可能会促进增加的增殖和IL-4分泌,这表明CLLT细胞的潜在功能障碍.

研究的目的:

研究miR-155-5p在CLL T细胞BTLA水平表观遗传修饰中的作用.
在CLL患者中评估基于抗miR-155-5p的免疫治疗的安全性和有效性.

主要方法:

从CLL患者和健康人群中转移PBMCs,这些人具有miR-155-5p抑制剂 (INH) 和控制siRNA (NC).
定量逆转录PCR (RT-qPCR) 用于评估miR-155-5p水平.
西部涂抹或流细胞测量以测量T细胞中的BTLA蛋白表达.

主要成果:

在CLL患者和健康个体中,INH的传染导致miR-155-5p的十倍下调.
在任何一组的miR-155-5p沉默后,在T细胞中没有观察到BTLA蛋白表达的显著差异.
miR-155-5p的抑制没有影响T细胞群中的BTLA表达.

结论:

对抗miR-155-5p治疗药物的全身注射代表了对CLL的有利免疫疗法策略.
这种方法是安全的,因为它不会影响T细胞中的BTLA表达.
抗miR-155-5p治疗可能有利于CLL患者,CLL细胞BTLA水平受损.

关键词:

这就是BTLA.在 CLL CLL 中.在T细胞,T细胞.表观遗传修饰是一种表观遗传修饰.免疫疗法免疫疗法在 miR-155-5p 中使用.

更多相关视频

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...